Video

Dr. Edith Perez on Immune Checkpoint Inhibition in TNBC

Edith A. Perez, MD, the deputy director at large for the Mayo Clinic Cancer Center, discusses the potential for immune checkpoint blockage as treatment for patients with advanced breast cancer.

Edith A. Perez, MD, the deputy director at large for the Mayo Clinic Cancer Center, discusses the potential for immune checkpoint inhibition as treatment for patients with advanced breast cancer.

There has been a great deal of interest in CTLA-4, PD-1, and PD-L1 inhibitors as treatments across a variety of malignancies, Perez explains. These strategies were explored first in tumors that had demonstrated susceptibility to immunotherapies, such as melanoma, and are now being investigated in breast cancer.

Two presentations at the 2014 San Antonio Breast Cancer Symposium showed that immune checkpoint inhibition is effective in patients with breast cancer, notes Perez. These early studies demonstrated that further investigation is warranted for this treatment strategy in breast cancer.

At the meeting, results were presented from a phase Ib study that demonstrated clinical efficacy with the PD-1 inhibitor pembrolizumab in patients with triple-negative breast cancer (TNBC). In this study, in heavily pretreated patients, the objective response rate (ORR) was 18.5%. Additionally, a second small trial showed clinical efficacy for the PD-L1 inhibitor MPDL3280A in pretreated patients with TNBC.

Future research will focus on the discovery of a biomarker of response for the immune checkpoint inhibitors in breast cancer, Perez notes. Additionally, optimal combination strategies need to be uncovered, in order to further enhance the efficacy of these novel immunotherapies.

<<<

View more from the 2014 San Antonio Breast Cancer Symposium

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity